Vicki Sato resigns from Galapagos Board
09 January 2015 - 5:30PM
Mechelen,
Belgium; 9 January 2015 - Galapagos NV (Euronext:
GLPG) announces the resignation of Dr Vicki Sato as a
member of its Board of Directors, effective 31
December 2014.
Dr Sato has been a member of the
Galapagos Board since 2011. She is also a member of the
Bristol-Myers Squibb Board of Directors. Dr Sato is leaving
the Board of Galapagos to avoid any potential conflicts of
interest.
"We wish to thank Vicki for her
strong contribution to the evolution of Galapagos into a
full-fledged, mature therapeutic pipeline company," said Dr Raj
Parekh, Chairman of the Board of Directors of Galapagos. "We
wish Vicki much success going forward."
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising three Phase 2
programs, two Phase 1 studies, five pre-clinical, and 25 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG1205, a first-in-class inhibitor of GPR84, is
currently being tested in a Phase 2 Proof-of-Concept study in
ulcerative colitis patients. GLPG1690 is a first-in-class
compound that targets pulmonary diseases and is currently in a
Phase 1 study. AbbVie and Galapagos signed an agreement in
cystic fibrosis to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 started
Phase 1 last month, and corrector GLPG2222 is at the pre-clinical
candidate stage. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in
The Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking
statements
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1885420
Galapagos (LSE:GLPG)
Historical Stock Chart
From May 2024 to Jun 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2023 to Jun 2024